วารสาร

Apixaban Concentration according to Creatinine cle for Stroke prevention in patients with nonvalvular Atrial Fibrillation (ACCESS-AF study)
Original Article

Apixaban Concentration according to Creatinine cle for Stroke prevention in patients with nonvalvular Atrial Fibrillation (ACCESS-AF study)

Sittikorn Kulprasertsri, Jutikan Imsub, Sansanee Saengwanitch

Apixaban, one of direct oral anticoagulants (DOAC) initially approved in 2012, has been shown to be equivalent or superior to vitamin K antagonist (VKA) for stroke prevention and has lower rates of major bleeding in patient with nonvalvular atrial fibrillation (NVAF)

เมษายน - มิถุนายน 2568
Apixaban Concentration According to Creatinine Clearance in Non-Valvular Atrial Fibrillation Patients
Original Article

Apixaban Concentration According to Creatinine Clearance in Non-Valvular Atrial Fibrillation Patients

Pawittra Puangsuwan, Juthathip Suphanklang, Jutikan Imsub, Sansanee Sangwanit, Chesda Udommongkol

Direct factor Xa inhibitors oral anticoagulants (DOACs) including rivaroxaban, apixaban and edoxaban have been shown to be equivalent or superior to warfarin for prevention of stroke or systemic embolism and DOACs have lower rates of major bleeding in patients with non-valvular atrial fibrillation (NVAF).

ตุลาคม - ธันวาคม 2565